GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Efavirenz (Sustiva)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

The interacting-drug recommendations are preserved from the historical page and require comparison with current HIV guidance.

Check source scope before reading a dose

NIH adult ARV table: Efavirenz

Product / population
Adults with HIV; product-specific renal recommendations.
Renal method
CrCl (mL/min), usually Cockcroft-Gault.
Source revision
Not established
Retrieved
2026-09-05
Local review status
Source-read local summary; source-specific recommendations are not automatically interchangeable.
Professional

NIH adult ARV table: Efavirenz

Open original reference

NIH ClinicalInfo HIV guidelines · Adults with HIV; product-specific renal recommendations.

Renal method: CrCl (mL/min), usually Cockcroft-Gault.
Source date: Not established
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

NIH dose and renal statement

Adults: 600 mg orally daily, fasting, preferably at bedtime; renal dose modification is not required.

efavirenz:nih-arv-efavirenz-1 · Source locator: Appendix B: Efavirenz row

Source identity and provenance
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-09-05
Renal-function method
CrCl (mL/min), usually Cockcroft-Gault.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
621555e79c945b07c76709444f24d00fbea134977a115a55f96c581962531034

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=efavirenz&s1=nih-arv-efavirenz&h1=e9637c298d28a6554a69157b29172f3efff6e83441cffc722b8f738bca640560